A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 1/1/2014 |
| Start Date: | November 2012 |
| End Date: | December 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
immunogenicity of single escalating doses PF-06342674.
immunogenicity of single escalating doses PF-06342674.
Inclusion Criteria:
- Male subjects and female of non-childbearing potential subjects between the ages of
18 and 55.
- BMI between 18.5 to 32 kg/m2.
- Total body weight ≥40 kg and ≤120 kg.
Exclusion Criteria:
- Previous treatment with an antibody within 6 months prior to Day 1.
- Pregnant or nursing females; females of childbearing potential.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
We found this trial at
1
site
Click here to add this to my saved trials
